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Resistance index through EBUS in enlarged mediastinal lymph 
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Objective: The vascular resistive index (RI) is measured by Doppler 
ultrasound and can be correlating with certain disease states. In order 
to establish the range of RI in enlarged LN, a study of 100 patients was 
performed with EBUS-TBNA Duplex Doppler ultrasound.
Methods: Consecutive patients with enlarged mediastinal LN were 
examined. 100 patients who had RI determined were included. All 
patients underwent surgical lymph node sampling to establish the rela-
tionship between histology (malignant or non- malignant) and RI.
Results: 152 pts were examined to include 100 in whom we were able 
to measure RI (54 male, 46 female, mean age 49y.). In 52 we were not 
able to visiualise the vessel. The histology revealed malignancy in 70 
cases and the RI was signiﬁcantly higher in those than in patients with-
out malignancy. Using the Youden Index we calculated a RI of 0,69 as 
the cut- off point for best discrimination (sensitivity 91,4 %, speciﬁcity 
90 %, p< 0,001). The AUC was 0,965 with an excellent discriminatory 
power (95 % conﬁdence interval 0,931 to 0,998) 
Conclusion: These results suggest that an increased RI seems to be 
highly correlated with a malignant histology. Conversely, a benign 
biopsy result through EBUS TBNA with a low RI may allow to forgo 
further testing.
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The role of whole-body FDG PET/CT, Tc 99m mdp bone 
scintigraphy, and serum alkaline phosphatase in detecting bone 
metastasis in patients with newly diagnosed lung cancer
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Background: Bone scan and serum alkaline phosphatase concentration 
are used to detect bone metastasis in malignancy, although whole-body 
FDG PET/CT is being used increasingly.
Objectives: To compare the usefulness of whole-body FDG PET/CT, 
bone scan, and serum alkaline phosphatase in detecting bone metasta-
ses in patients with newly diagnosed primary lung cancer.
Methods: The electronic medical record database at our institution 
was queried to identify all patients with a new diagnosis of lung cancer 
between January 2004 and December 2005, who had a PET/CT, bone 
scan, and check of serum alkaline phosphatase concentration before 
treatment. We retrospectively reviewed all patients’ medical records 
and radiological reports, and conﬁrmed bone metastases by considering 
all available clinical information.
Results: One hundred eighty-two patients met the inclusion criteria. 
Bone metastases were conﬁrmed in 30 patients. The average inter-
val between PET/CT and bone scan was 8.5 ± 14.0 days. Forty-nine 
patients had stage 4 nonsmall cell lung cancer, and seven patients had 
extensive stage small cell lung cancer.
The sensitivities, speciﬁcities and accuracies of PET/CT, bone scan, 
and serum alkaline phosphatase concentration were noted in following 
table. The kappa statistics were calculated for the three modalities. The 
kappa value was 0.19 between PET/CT and bone scan, 0.03 between 
bone scan and serum ALP concentration, and 0.15 between serum 
ALP concentration and PET/CT. The low kappa values suggested poor 
agreement between the three modalities.
Conﬁrmation of bone metastasis
Conﬁrmation criteria Number of patients
Progressing bone lesion on follow-up scan (PET/CT or bone scan) 2
Conﬁrmed bone metastasis by simple radiography, CT, or MRI 22
Positive initial ﬁndings on both bone scan and PET/CT in the same bone lesion 
with symptoms 5
Histological conﬁrmation 1
Total 30
Sensitivity, speciﬁcity, and accuracy of PET/CT, bone scan,  
and serum ALP concentration
 Sensitivity Speciﬁcity Accuracy
Positive 
predictive 
value
Negative 
predictive 
value
FDG PET/CT 93.3% (28/30)
94.1% 
(143/152)
93.4% 
(171/182)
75.7% 
(28/37)
98.6% 
(143/145)
Bone scan 93.3% (28/30)
44.1% 
(67/152)
52.2% 
(95/182)
24.7% 
(28/113)
97.1% 
(67/69)
Serum ALP 26.7% (8/30) 94.1% (143/152)
83.0% 
(151/182) 47.1% (8/17)
86.7% 
(143/165)
Serum ALP + 
bone scan 26.7% (8/30)
97.3% 
(148/152)
85.7% 
(156/182) 66.7% (8/12)
87.1% 
(148/170)
 
Conclusions: FDG PET/CT and bone scan had similar sensitivity, but 
PET/CT had better speciﬁcity and accuracy than bone scan. PET/CT is 
more useful than bone scan for evaluating bone metastasis. However, in 
the advanced stage, because of its high speciﬁcity, bone scan comple-
mented with serum alkaline phosphatase is a cost-effective modality to 
avoid having to use PET/CT.
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Trans-esophageal EUS-guided fine-needle aspiration and core 
biopsy for undetermined mediastinal lesions
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Background and Aims: EUS-guided ﬁne-needle aspiration & core 
biopsy (EUS-FNA/CB) is a minimally invasive diagnostic modality 
for tissue conﬁrmation of gastrointestinal or adjacent lesions. It would 
be more valuable in tuberculosis-prevalent settings because in which 
lymph nodes often enlarge reactively. This study is aimed to evaluate 
the diagnostic yields of EUS-FNA/CB for undetermined mediastinal 
lesions, and further to assess its clinical value in patients with present 
or prior history of pulmonary tuberculosis. 
